TSHA — Taysha Gene Therapies, Inc.
—
Nasdaq ·
Health Care ·
Biotechnology ·
CIK 1806310 ·
Last close
$4.67
Market Cap
$1.52B
52W High
$7.30
52W Low
$3.06
ADV30
3,170,047
Next earnings
2026-11-04
Quarterly Fundamentals
Revenues vs Net Income (last 4 Q)
Assets vs Liabilities (last 4 Q)
| Period | Revenues | Gross profit | Op income | Net income | Assets | Cash | Liabilities |
|---|---|---|---|---|---|---|---|
| Jun 2026 | 0 | — | -50,782,000 | -46,639,000 | 470,433,000 | 455,407,000 | 83,167,000 |
| Mar 2026 | 0 | — | -43,486,000 | -42,410,000 | 300,351,000 | 276,576,000 | 88,407,000 |
| Dec 2025 | 5,485,000 | — | -28,300,000 | -27,851,000 | 343,320,000 | 319,767,000 | 96,382,000 |
| Sep 2025 | 0 | — | -34,024,000 | -32,733,000 | 316,554,000 | 297,344,000 | 97,565,000 |
Cashflow TTM (yfinance, fills SEC gap)
Operating CF
$-111,948,000
Investing CF
$-3,257,000
Financing CF
$275,352,000
CapEx
$-3,384,000
Dividends Paid
—
Buybacks
—
EPS Diluted TTM
$-0.38
As of
2026-08-16
Balance + Analyst (yfinance extras)
Retained Earnings
$-753,710,000
Inventory
—
Receivables
—
ST Investments
—
EBIT TTM
$-129,823,000
Pretax Income TTM
$-129,876,000
Interest Exp TTM
$53,000
Analysts
12
Yahoo Snapshot (yfinance, live)
Total Revenue
$5,485,000
EBITDA
$-151,988,000
Free Cash Flow
$-80,965,624
Enterprise Value
$1,236,991,360
Total Cash
$455,407,008
Total Debt
$56,714,000
Shares Out
325,833,545
Trailing EPS
$-0.41
Book Value
$0.74
ROE
-47.1%
ROA
-23.8%
Div Yield
—
Annual Trend (SEC EDGAR, last 4y)
Revenues vs Net Income (last 4y)
| FY end | Revenues | Op income | Net income | Assets | Liabilities | Equity | Op cash flow |
|---|---|---|---|---|---|---|---|
| Dec 2025 | 9,773,000 | -110,498,000 | -108,995,000 | 343,320,000 | 96,382,000 | 246,938,000 | -93,090,000 |
| Dec 2024 | 8,333,000 | -86,621,000 | -89,298,000 | 160,364,000 | 88,839,000 | 71,525,000 | -81,225,000 |
| Dec 2023 | 15,451,000 | -71,374,000 | -111,566,000 | 172,731,000 | 97,794,000 | 74,937,000 | -73,018,000 |
| Dec 2022 | 2,502,000 | -126,027,000 | -166,014,000 | 126,276,000 | 125,327,000 | 949,000 | -88,390,000 |
TTM Snapshot
Revenues TTM
—
NetIncome TTM
—
OpCashFlow TTM
—
Assets (Latest)
—
Forward EPS
$-0.46
Max Pain — expiry 2026-10-16
max pain strike: $5.00 · spot: $4.64 · call oi: 2,773 · put oi: 362
Expected Move to 2026-10-16:
±$0.70
(15.07%) —
implied range
$3.94 –
$5.34
· ATM straddle on $5.00 strike
Peers — same industry
| Ticker | Name | Market Cap | Last | Daily % |
|---|---|---|---|---|
| INBX | Inhibrx Biosciences, Inc. | $1.47B | $99.61 | — |
| IMCR | Immunocore Holdings plc | $1.58B | $30.72 | — |
| MAZE | Maze Therapeutics, Inc. | $1.45B | $26.05 | — |
| COAG | Hemab Therapeutics Holdings, Inc. | $1.62B | $34.74 | — |
| NVAX | NOVAVAX INC | $1.75B | $10.63 | — |
News headlines (Yahoo Finance, 1h cache)
Taysha Gene Therapies Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
2026-09-04 12:00 · Yahoo
Taysha Gene Therapies Inc (TSHA) (Q2 2026) Earnings Call Highlights: Rett Syndrome Program ...
2026-08-12 05:02 · Yahoo
Taysha Gene Therapies Q2 Earnings Call Highlights
2026-08-12 01:04 · Yahoo
Taysha Gene Therapies Reports Second Quarter 2026 Financial Results and Provides Corporate Update
2026-08-11 20:00 · Yahoo
Taysha Gene Therapies and Catalent Expand Strategic Partnership to Include Future Commercial Manufacturing Support of TSHA-102 Gene Therapy for Rett Syndrome
2026-08-03 12:00 · Yahoo
Taysha Gene Therapies (TSHA) is One of The Most Affordable Biotech Names to Invest In
2026-07-15 14:01 · Yahoo
Taysha's R&D Chief Sold $1.2 Million in Stock After a 149% Run
2026-07-12 18:15 · Yahoo
Taysha Gene Therapies Announces Multiple Presentations Highlighting its TSHA-102 Clinical Program at the 2026 IRSF Rett Syndrome Scientific Meeting
2026-06-25 20:01 · Yahoo
Taysha Gene Therapies Announces Pricing of Public Offering of Common Stock and Pre-Funded Warrants
2026-06-25 02:33 · Yahoo
Taysha Advances Rett Syndrome Programme as Pivotal Trial Enrollment Completes (TSHA)
2026-06-22 12:56 · Yahoo
Recent Insider Activity
No insider activity indexed for this ticker.